



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Anti-IL-13 [6A1] Bulk Size Ab04494-10.3-BT

This antibody was created using our proprietary Fc Silent™ engineered Fc domain containing key point mutations that abrogate binding to Fc gamma receptors.

This is a reformatted human IgG1 Fc Silent Fc Silent™ antibody, based on the original human IgG1 format, created for improved compatibility with existing reagents, assays and techniques.

Isotype and Format: Human IgG1, Fc Silent™, Kappa

Clone Number: 6A1

Alternative Name(s) of Target: IL13; Interleukin-13; P600

UniProt Accession Number of Target Protein: P35225

Published Application(s): inhibition, neutralization, SPR, ELISA

Published Species Reactivity: Human, Cynomolgus Monkey

Immunogen: The original antibody was generated by immunizing SJL mice with *E. Coli*-produced recombinant human IL-13.

Specificity: This antibody is specific for human IL-13. It cross-reacts with cynomolgus monkey IL-13.

Application Notes: The original format of this antibody (mouse IgG1) showed binding activity against *E. coli*-expressed recombinant human IL-13 in a sandwich ELISA with an EC_{50} of 0.049 and 0.039 $\mu\text{g/ml}$ for human and cynomolgus IL-13. The antibody also exhibited potent binding and neutralization activities against various forms of IL-13. In inhibition assays, the antibody showed IC_{50} values of 0.165 $\mu\text{g/ml}$ for blocking human IL-13 binding to IL-13R α 1 and 0.056 $\mu\text{g/ml}$ for IL-13 binding to IL-13R α 2. Moreover, it demonstrated strong neutralization capabilities with ND_{50} (neutralizing dose) values of 0.0783 $\mu\text{g/ml}$ for human IL-13 and 0.04 $\mu\text{g/ml}$ for cynomolgus IL-13, indicating its efficacy in inhibiting IL-13-induced TF-1 cell proliferation (where the ND_{50} value is the concentration of monoclonal antibody required to reduce TF-1 cell proliferation by 50%, in response to a set concentration of IL-13). Furthermore, the antibody effectively neutralized mammalian-expressed human IL-13 with an ND_{50} value of 0.037 $\mu\text{g/ml}$ and a recombinant Q130 human IL-13 variant with an ND_{50} value of 0.110 $\mu\text{g/ml}$. The binding affinity of the antibody was measured by SPR and found to be 32, 270, and 61.2 pM for det-1 tagged human IL-13, human IL-13, and cynomolgus IL-13, respectively (EP1802658B1).

Antibody First Published in: PMID:

Note on publication: The original publication describes the generation and characterization of an anti-human IL-13 antibody and its derivatives, including its humanization.

Product Form

Size: 1 mg Purified antibody in bulk size.

Purification: Protein A affinity purified

Supplied In: PBS only.

Storage Recommendation: Store at 4°C for up to 3 months. Note, this antibody is provided without added preservatives, it is therefore recommended this antibody be handled under sterile conditions. For longer storage, aliquot and store at -20°C.

Concentration: 1 mg/ml.

Important note – This product is for research use only. It is not intended for use in therapeutic or diagnostic procedures for humans or animals.